Pathologic evaluation of breast cancer after neoadjuvant therapy

Cheol Keun Park, Woo Hee Jung, Ja Seung Koo

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


Breast cancer, one of the most common cancers in women, has various treatment modalities. Neoadjuvant therapy (NAT) has been used in many clinical trials because it is easy to evaluate the treatment response to therapeutic agents in a short time period; consequently, NAT is currently a standard treatment modality for large-sized and locally advanced breast cancers, and its use in early-stage breast cancer is becoming more common. Thus, chances to encounter breast tissue from patients treated with NAT is increasing. However, systems for handling and evaluating such specimens have not been established. Several evaluation systems emphasize a multidisciplinary approach to increase the accuracy of breast cancer assessment. Thus, detailed and systematic evaluation of clinical, radiologic, and pathologic findings is important. In this review, we compare the major problems of each evaluation system and discuss important points for handling and evaluating NAT-treated breast specimens.

Original languageEnglish
Pages (from-to)173-180
Number of pages8
JournalJournal of Pathology and Translational Medicine
Issue number3
Publication statusPublished - 2016

Bibliographical note

Publisher Copyright:
© 2016 The Korean Society of Pathologists/The Korean Society for Cytopathology.

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology


Dive into the research topics of 'Pathologic evaluation of breast cancer after neoadjuvant therapy'. Together they form a unique fingerprint.

Cite this